$PFE

Three healthcare stocks—Pfizer (6.5% yield), Medtronic (3.6% yield with 48-year dividend streak), and Omega Healthcare (5.8% yield)—offer retirees attractive income streams amid aging demographics.

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.

Three dividend-yielding stocks face temporary challenges but offer strong fundamental value and 6.5-7% yields, positioning them for potential major rebounds.

Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

Arvinas and Pfizer secure FDA approval for VEPPANU, the first PROTAC protein degrader, for ESR1-mutated breast cancer based on Phase 3 data showing 43% progression-risk reduction.

Moderna beats revenue estimates with $389M vs. $227.97M consensus but shares fall 2.05% due to $2.22 per share litigation settlement charge.

Pfizer's 6.55% dividend yield offers attractive income but reflects patent cliff and pandemic revenue decline pressures. Strategic restructuring and Seagen acquisition signal transformation bid.

Pfizer's ELREXFIO cancer therapy shows superior efficacy in Phase 3 myeloma trial, but stock declines amid analyst skepticism about growth prospects.

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.

Dietary supplements market valued at $218.88B in 2026, expected to reach $430.39B by 2035 at 7.78% CAGR, driven by health consciousness and aging populations.

Global antibiotic resistance market to grow from $9.78B (2026) to $12.72B (2031) at 5.4% CAGR, driven by rising drug-resistant infections and antimicrobial innovation.

Sun Pharma agrees to acquire Organon for $14/share in all-cash deal, sending shares up 16.87% as women's health firm finds exit after struggling 2021 Merck spinoff.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

PTCL market valued at USD 800 million in 2025 to grow 7% annually through 2036, driven by emerging therapies and rising disease incidence. U.S. represents 68% of market.

Relay Therapeutics reports positive Phase 2 data for zovegalisib triplet combination in metastatic breast cancer, planning Phase 3 launch in early 2027.

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.